Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 1;37(1):57-63.
doi: 10.1097/PEP.0000000000001156. Epub 2024 Dec 24.

A Scoping Review of Chemotherapy-induced Peripheral Neuropathy-Related Gait Abnormalities in Children With Cancer

Regan Washist  1 , Dan Steventon, Paige Samuelson, Brittany Anderson, Patti Berg-Poppe, Samuel Milanovich
Affiliations

A Scoping Review of Chemotherapy-induced Peripheral Neuropathy-Related Gait Abnormalities in Children With Cancer

Regan Washist et al. Pediatr Phys Ther. .

Abstract

Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) with associated weakness, areflexia, neuropathic pain, and sensory loss, is a common occurrence in children treated for cancer. However, accurate, quantifiable descriptions of gait deviations due to CIPN are lacking. This scoping review explores common gait abnormalities in children with CIPN.

Methods: Using extensive database and manual literature reviews, 3 relevant studies were identified that assessed CIPN-related gait changes in children.

Results: Though each study used different methods to analyze gait patterns, decreased ankle dorsiflexion with slower and shorter gait were common findings across the studies. Changes to ankle dorsiflexion range of motion can lead to slower walking speeds and compensatory changes that can cause developmental effects on a child's gait.

Conclusions: Relevant research on the topic of CIPN-related gait abnormalities in children with cancer identifies knowledge gaps and the need for more studies on the effects of CIPN on children.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

References

    1. Johnston DL, Sung L, Stark D, Frazier AL, Rosenberg AR. A systematic review of patient-reported outcome measures of neuropathy in children, adolescents and young adults. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2016;24(9):3723–3728. doi:10.1007/s00520-016-3199-x - DOI - PMC - PubMed
    1. Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer Oxf Engl 1990. 2010;46(3):479–494. doi:10.1016/j.ejca.2009.12.008 - DOI - PubMed
    1. Frigeni B, Piatti M, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst JPNS. 2011;16(3):228–236. doi:10.1111/j.1529-8027.2011.00351.x - DOI - PubMed
    1. Gilchrist LS, Marais L, Tanner L. Comparison of two chemotherapy-induced peripheral neuropathy measurement approaches in children. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2014;22(2):359–366. doi:10.1007/s00520-013-1981-6 - DOI - PubMed
    1. Lavoie Smith EM, Li L, Hutchinson RJ, et al. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs. 2013;36(5):E49–60. doi:10.1097/NCC.0b013e318299ad23 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances